A study of NBI-74788 for the treatment of classic, 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH)

Trial Profile

A study of NBI-74788 for the treatment of classic, 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH)

Planning
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs NBI 74788 (Primary)
  • Indications Congenital adrenal hyperplasia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 01 Nov 2017 According to a Neurocrine Biosciences media release, the company expects to initiate this study in November 2017.
    • 09 Aug 2017 New trial record
    • 03 Aug 2017 According to a Neurocrine Biosciences media release, the company plans to initiate this study in the third quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top